A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.
M Bader S, Calleja DJ, Devine SM, Kuchel NW, Lu BGC, Wu X, Birkinshaw RW, Bhandari R, Loi K, Volpe R, Khakham Y, Au AE, Blackmore TR, Mackiewicz L, Dayton M, Schaefer J, Scherer L, Stock AT, Cooney JP, Schoffer K, Maluenda A, Kleeman EA, Davidson KC, Allison CC, Ebert G, Chen G, Katneni K, Klemm TA, Nachbur U, Georgy SR, Czabotar PE, Hannan AJ, Putoczki TL, Tanzer M, Pellegrini M, Lechtenberg BC, Charman SA, Call MJ, Mitchell JP, Lowes KN, Lessene G, Doerflinger M, Komander D.
M Bader S, et al. Among authors: lechtenberg bc.
Nat Commun. 2025 Apr 3;16(1):2900. doi: 10.1038/s41467-025-57905-4.
Nat Commun. 2025.
PMID: 40180914
Free PMC article.